Calendar | For Your Patients | PHA Main Site | Contact Us | About Us | Not a registered user? Sign up here.

Resource Library

Circulating Collagen Biomarker and Quality of Life in Pulmonary Arterial Hypertension

Zeenat Safdar


  Sign in to add a review

Leave a Comment

Conference: 2010 International PHA Conference and Scientific Sessions

Release Date: 06.24.2010

Presentation Type: Abstracts

Safdar Z. 
Baylor College of Medicine, Houston, TX, USA

BACKGROUNDPulmonary Arterial Hypertension (PAH) is characterized by pulmonary arterial hypertrophy and collagen deposition. Previously we reported elevated circulating markers of collagen turnover (PIIINP) and aldosterone in PAH that indicated worse clinical parameters (ATS 2008 and Chest 2007). Aim of this study was to determine the association of quality of life indices with collagen biomarker and clinical parameters.

METHODS39 PAH subjects enrolled from the Baylor PH Center had PIIINP levels measured. Six-minute walk distance (6MWD), New York Heart Association functional status (FC), and demographic data was obtained. Short form-36 (physical component summary (PCS) and mental component summary (MCS) and EuroQol (EQ-5D) were administered. Higher SF-36 and EQ-5D scores indicate better health. A simple linear regression with biomarker and clinical data as outcome variables, and SF-36 PCS and MCS and EQ-5D as predictor variables was done. To examine association between FC, and SF-36 and EQ-5D QOL, logistic regression was used and reported as odds ratios.

RESULTSMean age was 47±12 (mean±SD) and 6MWD was 382±105 meters. 19 subjects were FC I/II, and 17 were III. Lower circulating levels of PIIINP was associated with higher SF-36 MCS scores (p=0.041). Odds ratio for having FC I/II was higher in patients with higher PCS, MCS, and EQ-5D scores [0.81 (p=0.001), 0.87 p=0.014) and 0.77 (p=0.02) respectively].

CONCLUSIONSBetter quality of life was associated with lower circulating collagen marker levels, lower BDS scores and lower FC. Improved health status may be reflective of improved clinical parameters and vascular remodeling.